Neostigmine Methylsulfate is a pharmaceutical salt formed by ionic pairing of the active pharmacophore with a carefully selected counter-ion to optimise aqueous solubility, crystallinity, dissolution rate, and solid-state stability relative to the parent free form. Salt selection is a pivotal pharmaceutical development decision influencing polymorphic landscape, hygroscopicity, powder flow, compressibility, and bioavailability. Characterisation of Neostigmine Methylsulfate by XRPD, DSC, TGA, and dynamic vapour sorption is essential to define the approved solid-state form and ensure consistent quality across manufacturing batches.
Health-based exposure limits for Neostigmine Methylsulfate require formal periodic review as new toxicological evidence, clinical safety data, or regulatory agency assessments become available. Pharmaceutical manufacturers are expected to maintain a defined review cycle—typically every 3–5 years or triggered by significant new findings—and to update OEL, PDE,
